Regional immunotherapy in resectable squamous cell lung carcinoma. Analysis of a randomized study

Cancer Immunol Immunother. 1982;13(3):174-5. doi: 10.1007/BF00205383.


Patients with resectable squamous cell carcinoma were randomly allocated after surgery to receive either no further treatment (57 patients) or a single intrapleural injection of BCG (61 patients). No significant improvement in survival was observed in patients treated with BCG, even when their disease was staged as N0. There was a slight trend for the recurrence rate to be lower in patients classed as N0, but this was not significant.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • BCG Vaccine / therapeutic use*
  • Carcinoma, Squamous Cell / surgery
  • Carcinoma, Squamous Cell / therapy*
  • Humans
  • Immunotherapy
  • Lung Neoplasms / surgery
  • Lung Neoplasms / therapy*


  • BCG Vaccine